Advertisement

Topics

Therachon AG Company Profile

07:03 EST 10th December 2018 | BioPortfolio

Therachon is a clinical-stage global biotechnology company focused on developing medicines for rare diseases with significant unmet need. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is committed to translating the promise of its science into new treatments for patients with high unmet medical needs. For more information, visit www.therachon.com.


News Articles [7 Associated News Articles listed on BioPortfolio]

Therachon acquires GLyPharma

Rare disease firm Therachon AG is acquiring closely held GLyPharma Therapeutic Inc. for an undisclosed sum.

Therachon closes $60mm mezzanine financing

Rare disease-focused Therachon AG raised $60mm in a mezzanine financing led by Novo Holdings, which was joined by other new backers Cowen Healthcare Investments, Pfizer Ventures, and Tekla Capital Man...

Therachon raises $60M round

Novo Holdings leads Therachon's $60M round

Therachon raises $60 million in mezzanine financing for rare disease drugs

The Basel, Switzerland-based biotech company plans to trial the drug in achondroplasia patients next year.

Therachon Announces Start of Natural History Study in Children with Achondroplasia

Therachon AG, a clinical-stage biotechnology company focused on rare diseases, today announced the start of “Dreambird,” a natural history study of children with achondroplasi...

Therachon Raises $60 Million Mezzanine Financing to Advance Lead Program in Achondroplasia and to Expand Rare Disease Pipeline

- Jørgen Søberg Petersen, M.D., Ph.D., DMSc, MBA and Timothy Anderson to Join Board of Directors - Therachon AG, a clinical-stage biotechnology company focused on rare ...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Therachon

Therachon is developing an innovative therapy for achondroplasia, the leading cause of dwarfism in humans. Therachon’s therapy aims to restore normal bone growth and proporti...

Therachon AG

Therachon is a clinical-stage global biotechnology company focused on developing medicines for rare diseases with significant unmet need. The company’s lead pipeline candidat...

More Information about "Therachon AG" on BioPortfolio

We have published hundreds of Therachon AG news stories on BioPortfolio along with dozens of Therachon AG Clinical Trials and PubMed Articles about Therachon AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Therachon AG Companies in our database. You can also find out about relevant Therachon AG Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...


Corporate Database Quicklinks



Searches Linking to this Company Record